Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.47 |
| ▸ | CASP1 | P29466 | 6/20 | 0.47 |
| ▸ | CASP7 | P55210 | 6/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 6/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL905849 | 0.87 | ACHE (0.60) | ADRB1ALDH1A1CYP3A4CYP2C9CYP1A2 | |
| Hydrochloric Acid SCHEMBL27512588 | 0.86 | ACHE (0.58) | ADRB1ALDH1A1CYP3A4CYP2C9CYP1A2 | |
| SCHEMBL5258581 | 0.78 | ADRB1 (0.52) | ADRB1ALDH1A1ACHEHPGDKDM4E | |
| SCHEMBL3267135 | 0.76 | HTR2C (0.65) | ADRB1ALDH1A1CYP3A4CYP2C9CYP1A2 | |
| SCHEMBL30423191 | 0.76 | ADRB1 (0.50) | ADRB1ALDH1A1CYP1A2HSD17B10CASP1 | |
| SCHEMBL905866 | 0.76 | HTR6 (0.51) | ADRB1ACHEHTR6CA12CA1 | |
| SCHEMBL2792154 | 0.75 | ADRB1 (0.55) | ADRB1ALDH1A1CYP2C9CYP1A2HSD17B10 | |
| SCHEMBL20443370 | 0.75 | ADRB1 (0.52) | ADRB1ALDH1A1ACHEKDM4E | |
| Hydrochloric Acid SCHEMBL5368905 | 0.74 | ALDH1A1 (0.54) | ADRB1ALDH1A1CYP2C9CYP1A2HSD17B10 | |
| Hydrochloric Acid SCHEMBL3275509 | 0.73 | ADRB1 (0.54) | ADRB1ALDH1A1CYP3A4CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247633-B2 | Pyrimidine compounds and their use | BIOVITRUM AB (SE) | 2007-07-24 | — | — | US | disclosed |
| US-20040014767-A1 | Novel compounds and their use | BIOVITRUM AB, A SWEDISH CORPORATION | 2004-01-22 | — | — | US | disclosed |
| EP-1335907-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2003-08-20 | — | — | EP | disclosed |
| US-6593330-B2 | Central nervous system disorders; antiserotonine agents | BIOVITRUM (SE) | 2003-07-15 | — | — | US | disclosed |
| US-20020147200-A1 | Novel compounds and their use | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-10-10 | — | — | US | disclosed |
| WO-2002040456-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147200-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | ADRB1 275/4885ALDH1A1 288/4885CYP3A4 295/4885 |
| US-20040014767-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | ADRB1 275/4885ALDH1A1 288/4885CYP3A4 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.